Stocktoria
Praxis Precision Medicines, Inc. PRAX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-16
Praxis Precision Medicines, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $8.6M | $2.4M | $0 | — | — | — |
| R&D expense | $267.1M | $152.4M | $86.8M | $155.0M | $120.3M | $45.0M | $29.6M |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M | -$62.0M | -$35.8M |
| Income tax | $471,000 | — | — | — | $0 | -$8,000 | -$84,000 |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M | -$61.8M | -$35.5M |
| EPS (diluted) | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-3.94 | $-7.86 | — |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M | -$52.6M | -$33.4M |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M | -$125.6M | -$52.6M | -$33.5M |
| Cash & equivalents | $357.3M | $215.4M | $81.3M | $61.6M | $138.7M | $296.6M | $44.8M |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M | $292.7M | $303.2M | $47.7M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M | $41.9M | $15.7M | $7.6M |
| Shareholders' equity | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M | $287.5M | -$81.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | +249.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.